JP2021519087A5 - - Google Patents
Info
- Publication number
- JP2021519087A5 JP2021519087A5 JP2020551874A JP2020551874A JP2021519087A5 JP 2021519087 A5 JP2021519087 A5 JP 2021519087A5 JP 2020551874 A JP2020551874 A JP 2020551874A JP 2020551874 A JP2020551874 A JP 2020551874A JP 2021519087 A5 JP2021519087 A5 JP 2021519087A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- hdaci
- teff
- eff
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023210666A JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649265P | 2018-03-28 | 2018-03-28 | |
| US62/649,265 | 2018-03-28 | ||
| PCT/US2019/024693 WO2019191501A1 (en) | 2018-03-28 | 2019-03-28 | Use of histone modifiers to reprogram effector t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023210666A Division JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519087A JP2021519087A (ja) | 2021-08-10 |
| JP2021519087A5 true JP2021519087A5 (enExample) | 2022-04-04 |
| JP7447011B2 JP7447011B2 (ja) | 2024-03-11 |
Family
ID=68060769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551874A Active JP7447011B2 (ja) | 2018-03-28 | 2019-03-28 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
| JP2023210666A Pending JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023210666A Pending JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12173317B2 (enExample) |
| EP (2) | EP3773626B1 (enExample) |
| JP (2) | JP7447011B2 (enExample) |
| KR (2) | KR20200138325A (enExample) |
| CN (1) | CN112105368A (enExample) |
| AU (1) | AU2019243578B2 (enExample) |
| CA (1) | CA3094375A1 (enExample) |
| WO (1) | WO2019191501A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1814580B1 (en) | 2004-11-24 | 2016-08-10 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| US12173317B2 (en) * | 2018-03-28 | 2024-12-24 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector T cells |
| KR102069704B1 (ko) * | 2018-05-16 | 2020-01-23 | 고려대학교 산학협력단 | Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법 |
| US20210290742A1 (en) * | 2018-09-27 | 2021-09-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| KR20230019460A (ko) * | 2020-05-29 | 2023-02-08 | 상하이 준셀 테라퓨틱스 컴퍼니 리미티드 | 종양 침윤 림프구의 종자세포 배지 및 이의 용도 |
| GB202008957D0 (en) * | 2020-06-12 | 2020-07-29 | Autolus Ltd | Culture medium |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| US20250248946A1 (en) * | 2022-04-15 | 2025-08-07 | Turn Biotechnologies, Inc. | Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells |
| EP4519418A1 (en) * | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| EP1814580B1 (en) | 2004-11-24 | 2016-08-10 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| IL292038B2 (en) * | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| CN117731763A (zh) * | 2016-06-24 | 2024-03-22 | 麦克马斯特大学 | 过继细胞转移与溶瘤病毒组合疗法 |
| BR112020018049A2 (pt) * | 2018-03-07 | 2020-12-29 | Poseida Therapeutics, Inc. | Composições de cartirina e métodos para uso |
| US12173317B2 (en) * | 2018-03-28 | 2024-12-24 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector T cells |
| CA3111384A1 (en) | 2018-09-05 | 2020-03-12 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
-
2019
- 2019-03-28 US US17/042,022 patent/US12173317B2/en active Active
- 2019-03-28 CA CA3094375A patent/CA3094375A1/en active Pending
- 2019-03-28 EP EP19775917.8A patent/EP3773626B1/en active Active
- 2019-03-28 KR KR1020207031018A patent/KR20200138325A/ko active Pending
- 2019-03-28 KR KR1020267020047A patent/KR20260109954A/ko active Pending
- 2019-03-28 WO PCT/US2019/024693 patent/WO2019191501A1/en not_active Ceased
- 2019-03-28 CN CN201980030423.9A patent/CN112105368A/zh active Pending
- 2019-03-28 EP EP25226324.9A patent/EP4722350A2/en active Pending
- 2019-03-28 AU AU2019243578A patent/AU2019243578B2/en active Active
- 2019-03-28 JP JP2020551874A patent/JP7447011B2/ja active Active
-
2023
- 2023-12-14 JP JP2023210666A patent/JP2024037880A/ja active Pending
-
2024
- 2024-11-18 US US18/951,341 patent/US20250145953A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schneidawind et al. | Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation | |
| Hu et al. | Th17/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation | |
| Gattinoni et al. | T memory stem cells in health and disease | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen‐reactive regulatory T cells for use in transplantation | |
| Safinia et al. | Regulatory T cells: serious contenders in the promise for immunological tolerance in transplantation | |
| JP2022505194A5 (enExample) | ||
| Duffy et al. | Mesenchymal stem cell effects on T-cell effector pathways | |
| US8685728B2 (en) | Kit containing stem cells and cytokines for use in attenuating immune responses | |
| Kim et al. | Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease | |
| JP2019516754A5 (enExample) | ||
| JP2014526244A5 (enExample) | ||
| Geem et al. | Harnessing regulatory T cells for the treatment of inflammatory bowel disease | |
| Nardo‐Marino et al. | Emerging therapies in sickle cell disease | |
| Introna et al. | Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms | |
| FI3578201T3 (fi) | Menetelmiä ja koostumuksia luonnollisille tappajasoluille | |
| RU2014110897A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| Fu et al. | Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | |
| Xu et al. | Immunomodulatory effects of histone deacetylation inhibitors in graft-vs.-host disease after allogeneic stem cell transplantation | |
| Rotolo et al. | Innate iNKT cells: from biological insight to clinical impact | |
| Thiolat et al. | Treg-targeted IL-2/anti-IL-2 complex controls graft-versus-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation | |
| Gress et al. | Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation | |
| Ott et al. | Innate immune cellular therapeutics in transplantation | |
| Gagliani et al. | Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation | |
| RU2016102172A (ru) | Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 | |
| Bader et al. | Regulatory T cell approaches for graft-versus-host disease prevention |